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ABSTRACT
We previously showed that conjunctival miR-147b and miR-1285 were upregulated in Gambian adults with inflammatory
scarring trachoma, and miR-155 and miR-184 expression was strongly associated with conjunctival inflammation and
ocular Chlamydia trachomatis infection in children from Guinea-Bissau. We investigated whether the single or combined
expression of miR-147b, miR-1285, miR-155 and miR-184 was able to identify individuals with increased risk of incident or
progressive scarring trachoma. Conjunctival swab samples were collected from 506 children between the ages of 4 and 12
living in northern Tanzania. These 506 samples formed the baseline sample set of a 4-year longitudinal study.
Chlamydia trachomatis infection was diagnosed by droplet digital PCR and expression of miR-155, miR-184, miR-1285 and
miR-147b was tested by qPCR. Individuals were assessed for incidence and progression of conjunctival scarring by
comparison of conjunctival photographs taken at baseline and 4 years later. miR-184 and miR-155 were strongly associated
with inflammation and infection at baseline; however, no miR was associated with 4-year scarring incidence or progression.
miR-184 expression was more strongly downregulated during inflammation in non-progressors relative to progressors,
suggesting that a disequilibrium in the efficiency of wound healing is a significant determinant of progressive conjunctival
fibrosis.
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INTRODUCTION
Trachoma is a fibrotic disease, initiated by conjunctival infec-
tion with Chlamydia trachomatis (Ct) during childhood. It is cur-
rently estimated that 3.2 million people suffer with trachoma-
tous trichiasis and are at risk of sight loss (World Health Organi-
zation 2016).
Micro RNAs (miR) are post-transcriptional regulators of gene
expression. Individual miR can regulate hundreds of genes
(Ambros 2004) and single or small numbers of miR can have
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profound roles in the regulation of biological processes in health
and disease, including fibrosis (Cushing et al. 2011) and inflam-
mation (Rodriguez et al. 2007; Yao et al. 2012; Xiang et al. 2014). In
addition to aiding our understanding of the complex transcrip-
tional patterns associated with disease mechanisms, miRNA
can be used as predictors or biomarkers of disease. Previous
work in the murine genital tract model of C. muridarum infec-
tion demonstrated that a virulent, pathology-inducing variant
induced differential expression of host miR 24 h post-infection
relative to a variant that induced less inflammatory pathology
(Yeruva et al. 2014).
It is thought that the vast majority of individuals living in
trachoma-endemic communities are exposed to Ct throughout
childhood and that repeated episodes of infection and associ-
ated inflammation lead to progression of scarring disease and
eventually trichiasis. It is not understood why only some ex-
posed individuals progress to scarring disease whereas others
do not. A miR transcriptional signature that could classify those
at risk of scarring progression before the onset of clinical signs
could enhance our understanding of the disease process and
could be used as biomarkers of protective or adverse effects in
response to a Ct vaccine, if one wasmade available for testing in
human populations.
We previously identified that miR-147b and miR-1285 were
upregulated during inflammatory trachomatous scarring in
Gambian adults (Derrick et al. 2013), and that differential expres-
sion of miR-184 and miR-155 was strongly associated with ocu-
lar Ct infection and active trachoma in children from Guinea-
Bissau (Derrick et al. 2016). We investigated whether these four
miR could predict trachomatous scarring progression.
METHODS
This study was approved by the London School of Hygiene and
Tropical Medicine ethics committee, the Tanzania National In-
stitute for Medical Research ethics committee and the Kiliman-
jaro Christian Medical Centre ethics committee and it adhered
to the tenets of the Declaration of Helsinki.
Conjunctival swabs were collected using standardmethodol-
ogy (Keenan et al. 2010; Last et al. 2014) from 506 children in the
West Kilimanjaro region of northern Tanzania, prior to the intro-
duction of MDA. These 506 children formed the baseline sample
set of a cohort (totalling 666 children) seen every 3 months for
4 years. MDAwas initiated 6months after baseline and three an-
nual rounds were given; the last dose was given 18months prior
to the final timepoint. High-resolution photographs were taken
prior to swab sample collection. Swabs were stored in RNAlater R©
(Thermo Fisher Scientific, Waltham, USA) until total RNA and
DNA extraction (Norgen Biotek Corp., Thorold, Canada). DNA
was tested for Ct infection using a ddPCR assay described else-
where (Roberts et al. 2013). RNA was reverse transcribed using
TaqMan R© MicroRNA Reverse Transcription Kit (Thermo Fisher
Scientific) and qPCR was performed on a VIIA7 thermal cy-
cler using TaqMan small RNA assays (Thermo Fisher Scientific)
for endogenous control U6, miR-155-5p, miR-184, miR-147b and
miR-1285. To investigate the mRNA expression of matrix met-
alloproteinase 7 (MMP7) and endogenous control HPRT1, RNA
was reverse transcribed using SuperScript R© VILO cDNA synthe-
sis kit (Thermo Fisher Scientific) and qPCR was performed on a
VIIA7 thermal cycler using TaqMan Low Density Array microflu-
idic cards (Thermo Fisher Scientific).
Of the 506 individuals seen at baseline, 346 were seen 4 years
later (31.6% loss to follow-up) and high-resolution photographs
were taken. Baseline photographs were graded for clinical signs
using the WHO 1981 FPC grading system (Dawson, Jones and
Tarizzo 1981). For analysis of clinical signs at baseline, follicu-
lar (F) and papillary (P) inflammation scores were combined into
a single inflammation score as follows: F0 and P0 = no inflam-
mation, F1 and/or P1/P2 = mild inflammation, F2/F3 and/or P3
= active trachoma. Scarring (C) scores 2 and 3 were combined
for analysis due to the small number in each group; thus, scar-
ring groups were as follows: C0 = no scarring, C1 = mild scarring
and C2/3 = moderate scarring. Baseline and 4-year photographs
were compared side by side by an experienced clinical trachoma
grader to identify individuals with incident (the appearance of
any new scar tissue) or progressive (an increase in the amount
of scar tissue) scarring (Burton et al. 2015). Statistical analyses
were performed in R (www.r-project.org). Thirteen samples were
removed from the analysis during quality control (endogenous
control U6 cycle threshold value (CT) > mean ± (2 × standard
deviation)). Delta CT (CT) values were calculated using U6, and
40-CT values were used in the analysis to reflect the direction
of expression.
RESULTS AND DISCUSSION
At baseline, the median age was 7.5 (range 4–12) and 49.6% of
children were male. 97.4% were of Maasai ethnicity; others were
Chaga, Sonjo and Pare. A total of 78 individuals had Ct infec-
tion (15.4%), 152 (30%) of individuals had no inflammation, 171
(33.8%) had mild inflammation and 183 (36.2%) of individuals
had active trachoma (defined by the grading system described
above). No conjunctival scarring was seen in 71.9% of individ-
uals at baseline, 23.5% had mild scarring (C score 1) and 4.5%
of individuals had moderate scarring. Of the 78 Ct infections at
baseline, 80.8% were found in individuals with active trachoma.
Consistentwith our previous results in children fromGuinea-
Bissau (Derrick et al. 2016), miR-1285 and miR-147b were not as-
sociatedwith any clinical phenotypes or infection,whereasmiR-
184 and miR-155 were strongly associated with inflammation
and infection (Table 1). miR-155 was upregulated in inflamma-
tion and infection andmiR-184was downregulated.miR-155 has
many roles in formation and development of immune cells and
in regulating immune response pathways (reviewed in Vigorito
et al. 2013). miR-155 has recently been shown to be involved in
murine bone marrow-derived dendritic cell activation following
Chlamydia muridarum infection (Gupta et al. 2016). The observed
upregulation of miR-155 probably reflects the increased pres-
ence and activity of immune cells in the conjunctival epithelium
and its associated lymphoid tissue during ocular Ct infection
and inflammation.miR-184 is strongly expressed in the conjunc-
tival epithelium and its downregulation is thought to activate
the Wnt pathway and promote neovascularisation in response
to ocular epithelial injury (Takahashi et al. 2015; Zong et al. 2016).
miR-184 negatively regulates the Wnt receptor frizzled-7 and a
miR-184 mimic inhibited Wnt signalling in a murine ocular in-
jury model (Takahashi et al. 2015). MMP7 is transcriptionally reg-
ulated by β-catenin, a Wnt signal transducer, and in malignant
tissues and chronic kidney disease MMP7 expression is posi-
tively correlated with Wnt activation (Brabletz et al. 1999; Craw-
ford et al. 2001; Machin et al. 2002; He et al. 2012). Upregulation of
MMP7 and enrichment of genes in the Wnt pathway have previ-
ously been reported in individuals with scarring trachoma and
trichiasis (Holland et al. 2010; Burton et al. 2011). We investigated
whether the downregulation of miR-184 expression was corre-
lated with an upregulation of MMP7 expression as a surrogate
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Table 1. Multivariate linear regression results showing associations of clinical and infection status at baseline with miR expression.
miR-1285 miR-147b miR-155 miR-184
P value OR (CI)a P value OR (CI)a P value OR (CI)a P value OR (CI)a
Mild inflammation 0.242 1.19 (0.89–1.59) 0.043 1.44 (1.01–2.05) 0.027 1.36 (1.04–1.78) 3.44 × 10–4 0.61 (0.47–0.80)
Active trachoma 0.937 1.01 (0.73–1.40) 0.156 1.33 (0.90–1.98) 5.26 × 10–5 1.89 (1.39–2.57) 4.46 × 10–8 0.43 (0.32–0.58)
Mild scarring 0.169 1.23 (0.92–1.65) 0.628 1.09 (0.76–1.56) 0.369 1.13 (0.86–1.49) 0.252 1.17 (0.89–1.53)
Moderate scarring 0.325 0.75 (0.43–1.32) 0.061 0.52 (0.26–1.03) 0.033 0.56 (0.33–0.95) 0.425 0.81 (0.48−1.36)
Ct infection 0.254 1.22 (0.86–1.74) 0.559 1.13 (0.74–1.73) 4.22 × 10–8 2.53 (1.83–3.51) 1.72 × 10–6 0.45 (0.33–0.62)
Age 0.008 0.92 (0.87–0.98) 0.583 0.98 (0.91–1.05) 0.577 0.98 (0.93–1.04) 0.028 1.06 (1.01–1.12)
Female 0.369 0.90 (0.71-1.13) 0.902 1.02 (0.77–1.35) 0.50 1.07 (0.87–1.34) 0.606 0.95 0.76–1.17)
aOR = odds ratio; CI = 95% confidence intervals.
Unadjusted P values are shown. Correcting for multiple comparisons using Bonferroni adjustment, P values <0.0125 would be considered significant (highlighted in
bold). Data from 493 individuals (13 samples excluded from the 506 baseline samples during quality control) were included in these models. miR expression was the
linear-dependent variable and clinical signs, infection status, age and sex were independent variables.
Figure 1. Principle component plot of the expression of miR-184, miR-155, miR-147b and miR-1285 at baseline. Scarring progressors (1; blue) and non-progressors
(0; red) are overlaid.
marker for Wnt pathway activation. In these baseline samples
however there was a marginally positive correlation between
MMP7 expression andmiR-184 expression (P= 0.053, adjusted R2
= 0.006). These samples consisted ofmixed cell populations, and
thus correlations between miR and effector expression should
be examined in single cells or epithelial cells.
Of the 346 individuals thatwere seen 4 years later, 262 (75.7%)
had no evidence of new scar tissue. Progressive or incident scar-
ring was identified in 84 individuals (24.3%) and there were no
individuals that showed a reduction in the amount of scar tissue.
Principle component analysis of the expression of miR-155,
miR-184, miR-147b and miR-1285 did not differentiate scarring
progressors and non-progressors (Fig. 1). Although there was
slight separation along principle component one (PC1), it was
not significant (P = 0.113, OR = 1.14 (0.97–1.34)). In univariate
models (adjusting for age and sex), expression levels of the four
miR at baseline were not associated with scarring progression
(Table 2). Mild inflammation, active trachoma, and mild and
moderate scarring at baseline were strongly associated with
scarring progression 4 years later.
In a stepwise multivariate logistic regression model, includ-
ing all miR and clinical phenotypes a priori, inflammation, scar-
ring and miR-184 expression were retained as the variables that
best explained variation in progression status. Interestingly, an
increase in miR-184 expression was associated with increased
risk of progression (P = 0.041, OR = 1.3). Further investigation of
miR-184 expression in progressors and non-progressors, anal-
ysed by inflammatory score categories, revealed that miR-184
was more strongly downregulated in the presence of inflamma-
tion in non-progressors relative to scarring progressors (Fig. 2).
Receiver-operating characteristic curves testing the ability of in-
flammation and scarring scores at baseline to predict scarring
progression 4 years later had an area under the curve (AUC) of
0.792; however, this was not significantly improved by the addi-
tion of miR-184 expression (AUC = 0.801), or in fact by the addi-
tion of all four miR (AUC = 0.802).
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Table 2. miR expression and clinical signs at baseline associated with 4-year scarring progression.
Univariate models Stepwise best fit
P OR (CI)a P OR (CI)a
Mild inflammation 0.0017 4.21 (1.80–11.13) 0.0057 3.77 (1.54–10.34)
Active trachoma 2.75 × 10−7 10.83 (4.62–29.01) 1.81 × 10−5 8.74 (3.41–25.21)
Mild scarring 2.56 × 10−10 7.15 (3.91–13.28) 3.19 × 10−7 5.33 (2.82–10.19)
Moderate scarring 1.61 × 10−4 7.13 (2.56–20.26) 0.0055 4.62 (1.56–13.95)
Ct infection 0.097 1.73 (0.89–3.27)
miR-1285 0.163 1.17 (0.94–1.45)
miR-147b 0.076 1.17 (0.98–1.41)
miR-155 0.105 1.19 (0.96–1.47)
miR-184 0.972 1.00 (0.82–1.23) 0.041 1.30 (1.02–1.68)
aOR = odds ratio; CI = 95% confidence intervals.
Unadjusted P values are shown. Correcting for multiple comparisons using Bonferroni adjustment, P values <0.0063 would be considered significant (highlighted in
bold). Data from 338 samples were included (8 samples were excluded from the 346 individuals seen at 4 years during quality control). Scarring progression (binary)
was the dependent variable. Age and sex were adjusted for in all models. The stepwise best-fit model initially included all independent variables tested in univariate
analyses and removed them one by one, finally only retaining variables that best describe variation in the dependent variable.
Figure 2. miR-184 expression was more strongly downregulated during inflam-
mation in non-progressors relative to scarring progressors. Inflammatory score
0 = no inflammation, 1 = mild inflammation, 2 = active trachoma. Differences
between groups were tested using Student’s t-test and were adjusted using Bon-
ferroni correction. Boxes show the interquartile range of miR expression and
the bold black central line shows the median. The number of individuals in
each group (n = x) is shown inside each box. Grey-filled boxes show miR ex-
pression in scarring progressors and white-filled boxes show miR expression in
non-progressors. FC = fold change.
These data show that the presence of scarring and inflam-
mation at baseline, but not chlamydial infection, is associated
with scarring progression 4 years later. Unfortunately, miR-184,
miR-155, miR-147b andmiR-1285 do not show potential to serve
as biomarkers to predict individuals at risk of developing further
scarring. It is possible that other miR that are not involved in the
acute response to Ct infection or in late-stage scarring regulate
the pathways leading to disease progression. In order to iden-
tify these miR, expression should be investigated in longitudi-
nal samples collected along the continuum of disease. We found
that scarring progressors did not downregulate miR-184 during
inflammation as much as non-progressors. This might suggest
that scarring progressors hadweaker activation of theWnt path-
way and neovascularisation during or following inflammation,
and that inefficient wound healing could contribute to chronic
fibrosis. At baseline, there was no inverse correlation between
miR-184 and the expression of MMP7, a surrogate marker of
Wnt pathway activation. The expression ofMMP7 and otherWnt
pathway members should also be investigated in longitudinal
samples to assess the potential contribution of the Wnt path-
way to disease progression. Whilst a miR biomarker for pro-
gressive scarring trachoma has so far not been identified in tra-
choma, further investigation of miR-184, the WNT pathway and
efficiency of wound healing might inform our knowledge of the
pathology of scarring trachoma.
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